Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

28.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
28.0K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

998
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
998
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.

Thrombosis research·2024
Same author

[Acquired hemophilia and pregnancy: A necessarily multidisciplinary approach].

La Revue de medecine interne·2022
Same author

[Identification of factors associated with performance in objective structured clinical examination in Rouen medical school].

La Revue de medecine interne·2022
Same author

Fecal incontinence subtype assessment (FI-SA): A new tool to distinguish among subtypes of fecal incontinence in a neurogenic population.

Clinics and research in hepatology and gastroenterology·2022
Same author

Gastric motility disorders and their endoscopic and surgical treatments other than bariatric surgery.

Journal of visceral surgery·2022
Same author

Disorders of anorectal motility: Functional defecation disorders and fecal incontinence.

Journal of visceral surgery·2022
Same journal

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Alimentary pharmacology & therapeutics·2026
Same journal

Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.

Alimentary pharmacology & therapeutics·2026
Same journal

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Alimentary pharmacology & therapeutics·2026
Same journal

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.

Alimentary pharmacology & therapeutics·2026
Same journal

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: Interpreting P-CAB Superiority for Antithrombotic Gastroprotection Beyond Acid Suppression. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Measuring Lactase Enzymatic Activity in the Teaching Lab
04:41

Measuring Lactase Enzymatic Activity in the Teaching Lab

Published on: August 6, 2018

117.3K

Lactose malabsorption in systemic sclerosis.

I Marie1, A-M Leroi2, G Gourcerol2

  • 1Department of Internal Medicine, Rouen University Hospital, and INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France. isabelle.marie@chu-rouen.fr.

Alimentary Pharmacology & Therapeutics
|September 29, 2016
PubMed
Summary
This summary is machine-generated.

Lactose malabsorption is common in systemic sclerosis (SSc) patients, affecting 44.3%. Identifying this through a lactose breath test can help manage digestive symptoms with a lactose-free diet.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.0K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K

Related Experiment Videos

Last Updated: Mar 14, 2026

Measuring Lactase Enzymatic Activity in the Teaching Lab
04:41

Measuring Lactase Enzymatic Activity in the Teaching Lab

Published on: August 6, 2018

117.3K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.0K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K

Area of Science:

  • Gastroenterology
  • Rheumatology
  • Clinical Nutrition

Background:

  • Systemic sclerosis (SSc) lacks studies on dietary factors, particularly lactose, and gastrointestinal (GI) dysfunction.
  • Gastrointestinal issues are prevalent in SSc patients, impacting quality of life.

Purpose of the Study:

  • Determine lactose malabsorption prevalence in SSc patients using lactose breath test.
  • Evaluate the correlation between lactose malabsorption and GI involvement in SSc.
  • Identify predictors of lactose malabsorption in SSc.

Main Methods:

  • Conducted lactose breath tests on 77 SSc patients and 20 controls.
  • Administered a digestive symptom questionnaire and calculated a global symptom score (GSS).

Main Results:

  • Lactose malabsorption occurred significantly more in SSc patients (44.3%) than controls (10%).
  • Malabsorption correlated with higher GSS, severe esophageal/small intestinal motor disorders, and joint involvement.
  • A lactose-free diet reduced digestive symptom GSS in affected SSc patients.

Conclusions:

  • Lactose malabsorption is frequent in systemic sclerosis patients.
  • Lactose breath test is a valuable, noninvasive tool for identifying SSc patients who may benefit from dietary lactose reduction.